How to talk to patients about JAK inhibitor safety | Victoria Ruffing
6:42
How to talk to patients about JAK inhibitor safety | Victoria Ruffing
2 жыл бұрын
BE MOBILE 1 and 2: How might bimekizumab impact axSpA clinical practice? | Fabian Proft
3:02
BE MOBILE 1 and 2: How might bimekizumab impact axSpA clinical practice? | Fabian Proft
2 жыл бұрын
BE COMPLETE and BE OPTIMAL: How might bimekizumab impact PsA clinical practice? | Philippe Carron
3:19
BE COMPLETE and BE OPTIMAL: How might bimekizumab impact PsA clinical practice? | Philippe Carron
2 жыл бұрын
The BE MOBILE 1 and 2 trials of bimekizumab in axSpA | Désirée van der Heijde
2:54
The BE MOBILE 1 and 2 trials of bimekizumab in axSpA | Désirée van der Heijde
2 жыл бұрын
The BE COMPLETE and BE OPTIMAL trials of bimekizumab in PsA | Joseph Merola
6:27
The BE COMPLETE and BE OPTIMAL trials of bimekizumab in PsA | Joseph Merola
2 жыл бұрын
Rituximab use in the COVID-19 era: Striking the right balance | Sebastian Sattui and David Jayne
13:17
Rituximab use in the COVID-19 era: Striking the right balance | Sebastian Sattui and David Jayne
2 жыл бұрын
Olokizumab: What makes it an effective and novel treatment for RA? | Roy Fleischmann
3:16
Olokizumab: What makes it an effective and novel treatment for RA? | Roy Fleischmann
2 жыл бұрын
Risankizumab for PsA: How will the KEEPsAKE 1 & 2 findings impact clinical practice? | Laura Coates
5:10
Risankizumab for PsA: How will the KEEPsAKE 1 & 2 findings impact clinical practice? | Laura Coates
2 жыл бұрын
The ARIAA trial of abatacept for subclinical arthritis | Jürgen Rech
7:05
The ARIAA trial of abatacept for subclinical arthritis | Jürgen Rech
2 жыл бұрын
FDA approval of anifrolumab for SLE | Eric Morand
3:45
FDA approval of anifrolumab for SLE | Eric Morand
3 жыл бұрын
First COVAX Registry data on COVID-19 vaccine safety for patients with RMDs | Pedro Machado
4:29
First COVAX Registry data on COVID-19 vaccine safety for patients with RMDs | Pedro Machado
3 жыл бұрын
Risankizumab shows promise for PsA in the KEEPsAKE 2 trial | Andrew Ostor
3:39
Risankizumab shows promise for PsA in the KEEPsAKE 2 trial | Andrew Ostor
3 жыл бұрын
RESOLVE-1 fails to meet primary endpoint for lenabasum in patients with dcSSc | Robert Spiera
7:11
RESOLVE-1 fails to meet primary endpoint for lenabasum in patients with dcSSc | Robert Spiera
3 жыл бұрын
COSMOS: Further evidence for the benefits of guselkumab in PsA | Laura Coates
6:03
COSMOS: Further evidence for the benefits of guselkumab in PsA | Laura Coates
3 жыл бұрын
Repurposing rheumatology drugs for COVID-19: Interleukin inhibitors
19:11
Repurposing rheumatology drugs for COVID-19: Interleukin inhibitors
3 жыл бұрын
Repurposing rheumatology drugs for COVID-19: Hydroxychloroquine (with Alfred Kim)
16:51
Repurposing rheumatology drugs for COVID-19: Hydroxychloroquine (with Alfred Kim)
3 жыл бұрын
Repurposing rheumatology drugs for COVID-19: TNF inhibitors (with Philip Robinson)
16:40
Repurposing rheumatology drugs for COVID-19: TNF inhibitors (with Philip Robinson)
3 жыл бұрын
Repurposing rheumatology drugs for COVID-19: JAK inhibitors
10:49
Repurposing rheumatology drugs for COVID-19: JAK inhibitors
3 жыл бұрын
Repurposing rheumatology drugs for COVID-19: What do we know? (with Jinoos Yazdany)
13:06
Repurposing rheumatology drugs for COVID-19: What do we know? (with Jinoos Yazdany)
3 жыл бұрын
Study finds link between RA treatment and COVID-19 severity | Jeffrey Sparks and Zachary Wallace
8:06
Study finds link between RA treatment and COVID-19 severity | Jeffrey Sparks and Zachary Wallace
3 жыл бұрын
Five things rheumatologists can do to improve their telemedicine practice | Aruni Jayatilleke
1:40
Five things rheumatologists can do to improve their telemedicine practice | Aruni Jayatilleke
3 жыл бұрын
Three things rheumatologists can do to improve their telemedicine practice | Chris Phillips
1:10
Three things rheumatologists can do to improve their telemedicine practice | Chris Phillips
3 жыл бұрын
ACR 2020 | Denis Poddubnyy discusses the SKIPPAIN trial
5:16
ACR 2020 | Denis Poddubnyy discusses the SKIPPAIN trial
3 жыл бұрын
ACR 2020 | Richard Furie discusses the LILAC trial
4:47
ACR 2020 | Richard Furie discusses the LILAC trial
3 жыл бұрын
ACR 2020 | Marina Magrey comments on a phase 3 trial of tofacitinib in ankylosing spondylitis
4:25
ACR 2020 | Marina Magrey comments on a phase 3 trial of tofacitinib in ankylosing spondylitis
3 жыл бұрын
ACR 2020 | Anna Moltó discusses the TICOSPA trial
6:25
ACR 2020 | Anna Moltó discusses the TICOSPA trial
3 жыл бұрын
ACR 2020 | Atul Deodhar discusses a phase 3 trial of tofacitinib in ankylosing spondylitis
5:37
ACR 2020 | Atul Deodhar discusses a phase 3 trial of tofacitinib in ankylosing spondylitis
3 жыл бұрын
ACR 2020 | FAST trial suggests comparable CV safety of febuxostat vs allopurinol
4:15
ACR 2020 | FAST trial suggests comparable CV safety of febuxostat vs allopurinol
3 жыл бұрын
ACR 2020 | John Stone discusses the BACC Bay Tocilizumab Trial
6:48
ACR 2020 | John Stone discusses the BACC Bay Tocilizumab Trial
3 жыл бұрын
Пікірлер